Abstract
Background: New strategies are needed to improve the results of automatic measurement of the various parts of the ECG signal and their dynamic changes.
Methods: The EClysis software processes digitally‐recorded ECGs from up to 12 leads at 500 Hz, using strictly defined algorithms to detect the PQRSTU points and to measure ECG intervals and amplitudes. Calculations are made on the averaged curve of each sampling period (beat group) or as means ± SD for beat groups, after being analyzed at the individual beat level in each lead. Resulting data sets can be exported for further statistical analyses. Using QT and R‐R measured on beat level, an individual correction for the R‐R dependence can be performed.
Results: EClysis assigns PQRSTU points and intervals in a sensitive and highly reproducible manner, with coefficients of variation in ECG intervals corresponding to ca. 2 ms in the simulated ECG. In the normal ECG, the CVs are 2% for QRS, 0.8% for QT, and almost 6% for PQ intervals. EClysis highlights the increase in QT intervals and the decrease of T‐wave amplitudes during almokalant infusion versus placebo. Using the observed linear or exponential relationships to adjust QT for R‐R dependence in healthy subjects, one can eliminate this dependence almost completely by individualized correction.
Conclusions: The EClysis system provides a precise and reproducible method to analyze ECGs. A.N.E. 2002;7(4):289–301
Keywords: automated ECG measurements, QT interval correction, R‐R, T wave
REFERENCES
- 1. Jackman WM, Friday KJ, Anderson JL, et al. The Long QT Syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115–172. [DOI] [PubMed] [Google Scholar]
- 2. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993;72:23B–25B. [DOI] [PubMed] [Google Scholar]
- 3. Yan G‐X, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long‐QT syndrome. Circulation 1998;981928–1936. [DOI] [PubMed]
- 4. Lazzara R. Mechanistic and clinical aspects of acquired long QT syndromes. Ann NY Acad Sci 1992;644:48–56. [DOI] [PubMed] [Google Scholar]
- 5. Kasanuki H, Ohnishi S, Tamura K, et al. Acquired long QT syndrome due to antiarrhythmic drugs and bradyarrhyth‐mias. Ann NY Acad Sci 1992;644:57–73. [DOI] [PubMed] [Google Scholar]
- 6. Surawicz B, Knoebel S. Long QT: Good, Bad or Indifferent J Am Coll Cardiol 1984;4:398–413. [DOI] [PubMed] [Google Scholar]
- 7. Roden DM, Woosley RL. QT prolongation and arrhythmia suppression. Am Heart J 1985;109:411–415. [DOI] [PubMed] [Google Scholar]
- 8. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of repolarization: Theoretic considerations and clinical observations. Am Heart J 1985;109:421–430. [DOI] [PubMed] [Google Scholar]
- 9. Singh BN, Sarma JSM, Zhang Z‐H, et al. Controlling cardiac arrhythmias by lengthening repolarization: Rationale from experimental findings and clinical considerations. Ann NY Acad Sci 1992;644:187–209. [DOI] [PubMed] [Google Scholar]
- 10. Vaughn Williams EM. Delayed ventricular repolarization as an antiarrhythmic principle. Eur Heart J 1985;6(Suppl. D): 145–149. [DOI] [PubMed] [Google Scholar]
- 11. Houltz B, Darpö B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsade de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. PACE 1998;21: 1044–1056. [DOI] [PubMed] [Google Scholar]
- 12. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. CAST and beyond. Implications of the cardiac arrhythmia suppression trial. Circulation 1990;81: 1123–1127. [DOI] [PubMed] [Google Scholar]
- 13. Fontaine G. A new look at torsade de pointes. Ann NY Acad Sci 1992;644:157–177. [DOI] [PubMed] [Google Scholar]
- 14. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsade de pointes occurring in association with terfenadine use JAMA 1990;264: 2788–2790. [PubMed] [Google Scholar]
- 15. Wiley JF II, Gelber ML, Henretig FM, et al. Clinical and laboratory observations. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992;120: 799–802. [DOI] [PubMed] [Google Scholar]
- 16. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290–291. [DOI] [PubMed] [Google Scholar]
- 17. De Ponti F, Poluzzi E, Montanaro N. QT‐interval prolongation by noncardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1–18. [DOI] [PubMed] [Google Scholar]
- 18. Committee for Proprietary Medicinal Products (CPMP): Points to consider: The assessment of the potential for QT interval prolongation by noncardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. December 1997.
- 19. Bonate PL, Russell T. Assessment of QTc prolongation for noncardiac‐related drugs from a drug development perspective. J Clin Pharmacol 1999;39:349–358. [DOI] [PubMed] [Google Scholar]
- 20. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by nonantiarrhyth‐mic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47: 219–233. [DOI] [PubMed] [Google Scholar]
- 21. Cavero I, Mestre M, Guillon J‐M, et al. Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Exp Opin Pharmacother 2000; 1:947–973. [DOI] [PubMed] [Google Scholar]
- 22. Savelieva I, Yi G, Guo X‐h, et al. Agreement and reproduc‐ibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol 1998;81: 471–477. [DOI] [PubMed] [Google Scholar]
- 23. Glancy JM, Weston PJ, Bhullar HK, et al. Reproducibility and automatic measurement of QT dispersion. Eur Heart 1996;17:1035–1039. [DOI] [PubMed] [Google Scholar]
- 24. Murray A, McLaughlin NB, Bourke JP, et al. Errors in manual measurement of QT intervals. Br Heart J 1994;71:386–390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Malik M, Bradford A. Human precision of operating a digitizing board: Implications for electrocardiogram measurements. PACE 1998;21:1656–1662. [DOI] [PubMed] [Google Scholar]
- 26. Puddu PE, Bernard PM, Chairman BR, et al. QT interval measurement by a computer assisted program: A potentially useful clinical parameter. J Electrocardiol 1982;15:15–22. [DOI] [PubMed] [Google Scholar]
- 27. McLaughlin NB, Campbell RWF, Murray A. Comparison of automatic QT measurement techniques in the normal 12 lead electrocardiogram. Br Heart J 1995;74:84–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Axenborg JE. A PC‐based on‐line system for physiological in vivo and in vitro experiments. Comput Meth Programs Biomed 1993;41:55–67. [DOI] [PubMed] [Google Scholar]
- 29. Willems JL, Arnaud P, van Bemmel JH, et al. Common standards for electrocardiography: Goals and main results. Meth Inf Med 1990;29:263–271. [PubMed] [Google Scholar]
- 30. Houltz B, Darpö B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by al‐mokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study. PACE 1998;21: 1044–1057. [DOI] [PubMed] [Google Scholar]
- 31. Wiesfeld ACP, Crijns HJGM, Tobé TJM, et al. Electrophar‐macologic effects and pharmacokinetics of almokalant, a new class 111 antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Am J Cardiol 1992;70:990–996. [DOI] [PubMed] [Google Scholar]
- 32. Svernhage E, Houltz B, Blomström P, et al. Early electro‐cardiographic signs of drug‐induced torsades de pointes. ANE 1998;3:252–260. [Google Scholar]
- 33. Bazett HC. An analysis of the time‐relations of electrocardiogram. Heart 1920;7:353–370. [Google Scholar]
- 34. Fridericia LS. Die Systolendauer in Elektrokardiogramm bei Normalen Menschen und bei Herzkranken. Acta Med Scand 1920;53:469–486. [Google Scholar]